The efficacy of drug treatments for dysthymia: A systematic review and meta-analysis

Psychological Medicine

Volumn 29, Issue 6, 1999, Pages 1273-1289

  De Lima, Maurício Silva ^a   Hotoph, M ^b   Wessely, S ^b  

^a Faculdade de Medicina   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINEPTINE; BENZHYDRYL DERIVATIVE; BUSPIRONE; DESIPRAMINE; DICLOFENSINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; IPRINDOLE; LEVACECARNINE; MAPROTILINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; OPIPRAMOL; PHENELZINE; PIZOTIFEN; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULPIRIDE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; U 23807A; UNCLASSIFIED DRUG; VILOXAZINE;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG CHOICE; DRUG EFFICACY; DYSTHYMIA; HUMAN; HYPERICUM PERFORATUM; META ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0032715150     PISSN: 00332917     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0033291799001324     Document Type: Article

References (75)

1. Adams, C., Duggan, L., Mari, J. & White, P. (1998). Cochrane Schizophrenia Group. In Cochrane Library (database on disk and CDROM). The Cochrane Collaboration; 1998, Issue 3. Update Software, 1998 (updated quarterly): Oxford.
2. Akiskal, H. S. (1983). Dysthymic disorder: psychopathology of proposed chronic depressive subtype. American Journal of Psychiatry 140, 11-20.
3. Altman, D. G. (1998). Confidence intervals for the number needed to treat. British Medical Journal 317, 1309-1312.
4. American Psychiatric Association (1980). Diagnostic and Statistical Manual of Mental Disorders (DSM-III), 3rd edn. APA: Washington, DC.
5. American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R ), 3rd edn, revised. APA: Washington, DC.
6. Anderson, I. M. & Tomenson, B. M. (1994). The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. Journal of Psychopharmacology 8, 238-249.
7. Bakish, D., Ravindran, A., Hooper, C. & Lapierre, Y. (1994). Psychopharmacological treatment response of patients with a DSM-III diagnosis of dysthymic disorder. Psychopharmacology Bulletin 30, 53-59.
8. Bella, R., Biondi, R., Raffaele, R. & Pennisi, G. (1990). Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. International Journal of Clinical Pharmacological Research 10, 355-360.
9. 2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatrica Scandinavica 83, 244-248.
10. Bohm, C., Robinson, D., Gammans, R., Shrotriya, R., Alms, D., Leroy, A. & Placchi, M. (1990). Buspirone therapy in anxious elderly patients: a controlled clinical trial. Journal of Clinical Psychopharmacology 10, 47S-51S.
11. Botte, L., Evrard, J. L., Gilles, C., Stenier, P. & Wolfram, C. (1992). Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression. Acta Psychiatrica Belgica 92, 355-369.
12. Boyer, P. & Lecrubier, Y. (1996). Atypical antipsychotic drug in dysthymia: placebo controlled studies of amisulpride versus imipramine, versus amineptine. European Psychiatry 11 (suppl. 3), 135S-140S.
13. Casacchia, M., Carolei, A., Barba, C., Frontoni, M., Rossi, A., Meco, G. & Zylberman, M. R. (1984). A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor. Pharmacopsychiatry 7, 122-125.
14. Cochrane Library (database on disk and CDROM) (1998). The Cochrane Collaboration; 1998, Issue 3. Update Software, 1998 (Updated quarterly): Oxford.
15. Costa e Silva, J. (1990). Traitement des dysthymies par de faibles doses d'amisulpride. Elude comparative amisulpride 50mg/j versus placebo. Annales De Psychiatrie 5, 242-249.
16. Davidson, J. & Turnbull, C. (1983). Isocarboxazide efficacy and tolerance. Journal of Affective Disorders 5, 183-189.
17. De Paula, A. J. M. & Omer, L. M. O. (1980). Diclofensine (Ro 8-4650), a new psychoactive drug: its efficacy and safety in nonpsychotic depression under double-blind placebo-controlled conditions. Current Therapeutic Research 28, 837-844.
18. Egger, M, Smith, G. D., Scheneider, M. & Mindler, C. (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629-634.
19. Georgia, E. H. (1984). Double-blind comparison of the efficacy and safety of nomifensine maleate vs placebo in depressed outpatients. Journal of Clinical Psychiatry 45, 43-46.
20. Gilbert, M. M. & Koepke, H. H. (1975). Oxazepam-protriptyline: a double-blind phase II evaluation of the efficacy and safety of the combination versus placebo in neurotic, depressed and anxious psychiatric outpatients. Current Therapeutic Research 18, 825-838.
21. Goldberg, H. L. & Finnerty, R. J. (1980). Trazodone in the treatment of neurotic depression. Journal of Clinical Psychiatry 41, 430-434.
22. Gwirtsman, H. E., Blehar, M. C., McCullough, J. P., Kocsis, J. H. & Prien, R. F. (1997). Standardized assessment of dysthymia: report of a National Institute of Mental Health Conference. Psychopharmacology Bulletin 33, 3-11.
23. Harrer, G. & Sommer, H. (1993). Therapie leichter/mittelschwerer depressionen mit Hypericum. (Therapy of mild or moderate depression with Hypericum.) Munchner Medizinische Wochenzeitschrift 135, 305-309.
24. Harrison, W., Rabkin, J., Stewart, J. W., McGrath, P. J., Tricamo, E. & Quitkin, F. (1986). Phenelzine for chronic depression : a study of continuation treatment. Journal of Clinical Psychiatry 47, 346-349.
25. Harrison, W. M. & Stewart, J. W. (1995). Pharmacotherapy of dysthymic disorder. In Diagnosis and Treatment of Chronic Depression (ed. J. H. Kocsis and D. N. Klein), pp. 124-145. The Guilford Press: New York.
26. Heller, A. H., Beneke, M., Kuemmel, B., Spencer, D. & Kurtz, N. M. (1990). Ipsapirone: evidence for efficacy in depression. Psychopharmacology Bulletin 26, 219-222.
27. Hellerstein, D. J., Yanowitch, P., Rosenthal, J., Samstag, L. W., Maurer, M., Kasch, K., Burrows, L., Poster, M., Cantillon, M. & Winston, A. (1993). A randomized double-blind study of ftuoxetine versus placebo in the treatment of dysthymia. American Journal of Psychiatry 150, 1169-1175.
28. Hotopf, M., Hardy, R. & Lewis, G. (1997a). Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. British Journal of Psychiatry 170, 120-127.
29. Hotopf, M., Lewis, G. & Normand, C. (1997b). Putting trials on trial -the costs and consequences of small trials in depression: a systematic review of methodology. Journal of Epidemiology and Community Health 51, 354-358.
30. Howland, R. H. (1991). Pharmacotherapy of dysthymia: a review. Journal of Clinical Psychopharmacology 11, 83-92.
31. Imlah, N. W. (1985). An evaluation of alprazolam in the treatment of reactive or neurotic (secondary) depression. British Journal of Psychiatry 146, 515-519.
32. Kivela, S. L. & Lehtomaki, E. (1987). Sulpiride and placebo in depressed elderly outpatients: a double-blind study. International Journal of Geriatric Psychiatry 2, 255-260.
33. Kocsis, J. H. (1992). Treatment of dysthymia with tricyclic and antidepressants. Clinical Neuropharmacology 15 (Suppl. 1), Pt. B, 149B.
34. Kocsis, J. H. (1997). Chronic depression: the efficacy of pharmacotherapy. In Dysthymia and the Spectrum of Chronic Depression (ed. H. S. Akiskal and G. B. Cassano), pp. 66-74. The Guilford Press: New York.
35. Kocsis, J. H., Frances, A. J., Mann, J. J., Sweeney, J., Voss, C., Mason, B. & Brown, R. P. (1985). Imipramine for treatment of chronic depression. Psychopharmacology Bulletin 21, 698-700.
36. Kocsis, J. H., Frances, A. J., Voss, C., Mann, J. J., Mason, B. J. & Sweeney, J. (1988a). Imipramine treatment for chronic depression. Archives of General Psychiatry 45, 253-257.
37. Kocsis, J. H., Frances, A. J., Voss, C., Mason, B. J., Mann, J. J. & Sweeney, J. (1988b). Imipramine and social-vocational adjustment in chronic depression. American Journal of Psychiatry 145, 997-999.
38. Kocsis, J. H., Sutton, B. M. & Frances, A. J. (1991). Long-term follow-up of chronic depression treated with imipramine. Journal of Clinical Psychiatry 52, 56-59.
39. Kocsis, J. H., Friedman, R. A., Markowitz, J. C., Leon, A. C., Miller, N. L., Gniwesch, L. & Parides, M. (1996). Maintenance therapy for chronic depression. A controlled clinical trial of desipramine. Archives of General Psychiatry 53, 769-774.
40. Lecrubier, Y., Boyer, P., Turjanski, S., Rein, W. & Amisulpride Study Group (1997). Amisulpride versus imipramine and placebo in dysthymia and major depression. Journal of Affective Disorders 43, 95-103.
41. McEvoy, J., Sheridan, W., Stewart, W. J., Ban, T., Wilson, W., Guy, W. & Schaffer, J. D. (1980). Viloxazine in the treatment of depressive neurosis: a controlled clinical study with doxepin and placebo. British Journal of Psychiatry 137, 440-443.
42. Magni, G., Garreau, M., Orofiamma, B. & Palmineri, R. (1989). Fengabine, a new GABAminetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics. Neuropsychobiology 20, 126-131.
43. Mulrow, C. D. & Oxman, A. D. (eds.) (1998). Cochrane Collaboration Handbook (updated April 1998). Available in The Cochrane Library (database on disk and CDROM). The Cochrane Collaboration & Update Software. Updated quarterly. Available from, BMJ Publishing Group: London.
44. Murphy, J. (1981). An evaluation of pyrisuccideanol maleate (nadex) in the treatment of mild to moderate depression in patients aged 55 years and over, presenting in general practice. Journal of Internal Medicine Research 9, 330-337.
45. Naylor, C. D. (1997). Meta-analysis and the meta-epidemiology of clinical research. British Medical Journal 315, 617-619.
46. Oakley-Brown, M., Bech, P., Churchill, R., Gill, D., Hazell, P., Trivedi, M. & Wessely, S. (1998). Cochrane Depression, Anxiety and Neurosis Group. In The Cochrane Library (database on disk and CDROM). The Cochrane Collaboration; 1998, Issue 3. Update Software: Oxford. Updated quarterly.
47. Paykel, E. S., Hollyman, J. A., Freeling, P. & Sedgwick, P. (1988). Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. Journal of Affective Disorders 14, 83-95.
48. Petrie, W. M., McEvoy, J. P., Wilson, W. H., Ban, T. A. & Guy, W. (1980). Viloxazine in the treatment of depressive neurosis: a placebo and standard (imipramine) controlled clinical study. International Pharmacopsychiatry 15, 193-196.
49. Raskin, A. & Crook, T. H. (1976). The endogenous-neurotic distinction as a predictor of response to antidepressant drugs. Psychological Medicine 6, 59-70.
50. Ravindran, A. V. & Wiseman, R. (1997). A double-blind placebo-controlled study of sertraline in the treatment of dysthymic outpatients without major depression. Poster presented at the 150th American Psychiatric Association Annual Meeting, San Diego.
51. Reyntjens, A., Gelders, Y. G., Hoppenbrouwers, M. L. J. A. & Bussche, G. V. (1986). Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Development Research 8, 205-211.
52. Rickels, K., Gordon, P. E., Meckelnburg, R., Sablosky, L., Whalen, E. & Dion, H. (1968). Iprindole in neurotic depressed general practice patients: a controlled study. Psychosomatics 9, 208-214.
53. Rickels, K., Gordon, P. E., Jenkins, W., Sablosky, L., Vlachos, V. A., Weise, C. C., Whalen, E. M. & Wilson, D. A. (1971a). Combination of meprobamate and benactyzine (Deprol) and constituents in neurotic depressed outpatients. Diseases of the Nervous System 32, 457-467.
54. Rickels, K., Laquer, K. G., Rail, W. Y., Rosenfel, H., Schneider, B., Wagner, I. G. (1971b). The combination of protriptyline and oxazepam in depressed neurotic general practice patients. Psychosomatics 12, 341-348.
55. Rickels, K., Schneider, B., Pereira Ogan, J. Á., Perloff, M. M., Segal, A. & Vandervot, W. (1974). Pipradrol in mild depression: a controlled study. Journal of Clinical Pharmacology 14, 127-133.
56. Rowan, P. R., Paykel, E. S. & Parker, R. R. (1982). Phenelzine and amitriptyline: effects on symptoms of neurotic depression. British Journal of Psychiatry 140, 475-483.
57. Sackett, D. L., Richardson, W. S., Rosenberg, W. & Haynes, R. B. (1997). Evidence-based Medicine. How to Practice and Teach EBM. Churchill Livingstone: Edinburgh.
58. Shammas, E. (1977). Controlled comparison of bromazepam, amitryptyline, and placebo in anxiety-depressive neurosis. Diseases of the Nervous System 38, 201-207.
59. Shipley, G. S., Bishop, M. P. & Gallant, D. M. (1967). A controlled evaluation of U-23,807A in the neurotic depressive syndrome. Current Therapeutic Research 9, 514-516.
60. Song, F., Freemantle, N., Sheldon, T. A., House, A., Watson, P., Long, A. & Mason, J. (1993). Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. British Medical Journal 306, 683-687.
61. Standal, J. E. (1977). Pizotifen as an antidepressant. Acta Psychiatrica Scandinavica 56, 276-279.
62. Stewart, J., Quitkin, F., McGrath, P., Rabkin, J., Markowitz, J., Tricamo, E. & Klein, D. (1988). Social functioning in chronic depression: effect of 6 weeks of antidepressant treatment. Psychiatry Research 25, 213-222.
63. Stewart, J. W., Quitkin, F. M., Liebowitz, M. R., McGrath, P. J., Harrison, W. M. & Klein, D. F. (1983). Efficacy of desipramine in depressed outpatients. Response according to research diagnostic criteria diagnoses and severity of illness. Archives of General Psychiatry 40, 202-207.
64. Stewart, J. W., McGrath, P. J., Liebowitz, M. R., Harrison, W., Quitkin, F. & Rabkin, J. G. (1985). Treatment outcome validation of DSM-III depressive subtypes. Clinical usefulness in outpatients with mild to moderate depression. Archives of General Psychiatry 42, 1148-1153.
65. Stewart, J. W., McGrath, P. J., Quitkin, F. M., Harrison, W., Markowitz, J., Wager, S. & Leibowitz, M. R. (1989). Relevance of DSM-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo. Archives of General Psychiatry 46, 1080-1087.
66. Stewart, J. W., McGrath, P. J. & Quitkin, F. M. (1992). Can mildly depressed outpatients with atypical depression benefit from antidepressants? American Journal of Psychiatry 149, 615-619.
67. Stewart, J. W., McGrath, P. J., Quitkin, P. M., Rabkin, J. G., Harrison, W., Wager, S., Nunes, E., Ocepek Welikson, K. & Tricamo, E. (1993). Chronic depression: response to placebo, imipramine, and phenelzine. Journal of Clinical Psychopharmacology 13, 391-396.
68. Tetreault, L., Doucet, P., Blanchet, A. & Bordeleau, J. M. (1966). Evaluation comparative des proprietes antidepressives de l'opipramol, de l'imipramme et du placebo dans la depression nevrotique. L'Union Medique du Canada 95, 546-553.
69. Thase, M. E., Fava, M., Halbteich, U., Kocsis, J. H., Koran, L., Davidson, J., Rosenbaum, J. & Harrison, W. (1996). A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Archives of General Psychiatry 53, 777-784.
70. Tyrer, P., Seivewright, N., Ferguson, B., Murphy, S., Darling, C., Brothwell, J., Kingdon, D. & Johnson, A. L. (1990). The Nottingham Study of Neurotic Disorder: relationship between personality and symptoms. Psychological Medicine 20, 423-431.
71. Van der Velde, C. D. (1981). Maprotiline versus imipramine and placebo in neurotic depression. Journal of Clinical Psychiatry 42, 138-141.
72. Vanelle, J. M. (1997). Controlled efficacy study of fluoxetine in dysthymia. British Journal of Psychiatry 170, 345-350.
73. Versiani, M., Amrein, R. & Stabl, M. (1997). Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. International Clinical Psychopharmacology 12, 183-193.
74. Weissman, M. M., Leaf, P. J., Bruce, M. L. & Florio, L. (1988). The epidemiology of dysthymia in five communities: rates, risks, comorbidity and treatment. American Journal of Psychiatry 145, 815-819.
75. WPA Dysthymia Working Group (1995). Dysthymia in clinical practice. British Journal of Psychiatry 166, 174-183.